USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: Biomedical Frontiers, Inc.
City: Minneapolis
State: MN
Zip+4: 55413
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $174,250.00 3
SBIR Phase II $924,000.00 2

Award List:

SYNTHESIS OF HIGH MOLECULAR WEIGHT IRON CHELATORS

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bo Erik Hedlund , Principal Investigator
Award Amount: $44,000.00

SYNTHESIS OF HIGH MOLECULAR WEIGHT IRON CHELATORS

Award Year / Program / Phase: 1987 / SBIR / Phase II
Agency: HHS
Principal Investigator: Bo Erik Hedlund , Principal Investigator
Award Amount: $249,000.00
Abstract:
In chemical and biological systems, iron is both ubiquitous and highly reactive. in a variety of circumstances, there is great need for new approaches to the removal of iron or the control of its reactivity. biomedical frontiers has produced a series of high molecular weight iron chelators based on… More

MACROMOLECULAR CONTRAST AGENTS FOR MAGNETIC RESONANCE

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Hedlund, Bo E , Principal Investigator
Award Amount: $50,000.00

MACROMOLECULAR CONTRAST AGENTS FOR MAGNETIC RESONANCE

Award Year / Program / Phase: 1994 / SBIR / Phase II
Agency: HHS
Principal Investigator: Hedlund, Bo E , Principal Investigator
Award Amount: $675,000.00
Abstract:
Biomedical frontiers (bmf) has established that the iron chelator, deferoxamine, can be covalently bound to polymers and has demonstrated, in preclinical studies, that these conjugates can be used therapeutically as antioxidants. we will evaluate these compounds, following saturation with ferric… More

Tumor Growth Inhibition by Iron Deprivation

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bo Erik Hedlund
Award Amount: $80,250.00
Abstract:
This research will determine the potential utility of novel high molecular weight iron chelatorsas anti-cancer agents or adjuncts to other iron-depriving therapeutic strategies in the treatment ofcancer. This approach takes advantage of the elevated iron requirements of many types of tumors. Aseries… More